10QSB

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10 - QSB

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (D)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarter ended March 31, 2006

Capacitive Deionization Technology Systems, Inc.

(Exact name of registrant as specified in its charter)

Nevada	86-0867960
(State of Jurisdiction)	(I.R.S. Employer
	identification No.)

4251 Kellway Circle, Addison, TX 75001

(Address of Principal executive offices)

972-934-1586

(Registrant's telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yes   X      No   

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes         No   X_

The number of shares outstanding of the registrant's $.0001 par value common stock as of April 30, 2006 was 25,626,662.

Capacitive Deionization Technology Systems, Inc.

Index			Page
Part I	Financial Information
	Item 1	Financial statements
		Balance Sheets as of March 31, 2006 and
		December 31, 2005	3
		Statements of Operations for the three
		months ended March 31, 2006 and 2005 and Cumulative Amounts Through March 31, 2006	4
		Statements of Cash Flows for the three
		months ended March 31, 2006 and 2005 and Cumulative Amounts Through March 31, 2006	5
		Notes to Financial Statements	6-8
	Item 2	Management's discussion and analysis
		of Financial Condition and Results
		of Operations	8
	Item 3	Controls and Procedures	9
Part II	Other Information
	Item 2	Unregistered Sales of Equity Securities	9
	Item 3	Defaults upon Senior Securities	10
	Item 6	Exhibits	10
Signature page			10

2

CAPACITIVE DEIONIZATION TECHNOLOGY SYSTEMS, INC.

(A Development Stage Entity)

BALANCE SHEETS

Assets

	March 31,	December 31,
	2006	2005
Current assets:	(Unaudited)	(Audited)
Cash	$       486,553	$          11,178
Note receivable	40,000	40,000
Total current assets	526,553	51,178
Furniture and equipment	180,657	138,222
Less accumulated depreciation	(30,388)	(24,030)
Total furniture and equipment	150,269	114,192
	$        676,822	$         165,370

Liabilities and Stockholders' Equity (Deficit)

Current liabilities:
Accounts payable	$        395,996	$         410,713
Wages payable	625,562	713,339
Accrued liabilities	691,144	615,633
Customer deposits	203,700	203,700
Notes payable and current portion of long-term debt,
less umamortized discount of $417,269 in 2006)	1,210,900	388,369
Notes payable - related parties	2,148,000	2,158,000
Total current liabilities	5,275,302	4,489,754
Other long-term debt	495,245	495,245
Commitments and contingencies	-	-
Stockholders' equity (deficit):
Preferred stock, $.0001 par value, 20,000,000 shares
authorized; none issued and outstanding	-	-
Common stock, $.0001 par value, 80,000,000 shares
authorized; 25,555,262 and 25,551,262 shares
issued and outstanding in 2006; 22,452,837
shares issued and outstanding in 2005	2,555	2,245
Additional paid-in capital	10,528,327	9,544,147
Accumulated deficit from previous operating activities	(3,523,977)	(3,523,977)
Deficit accumulated during the development stage	(12,096,430)	(10,842,044)
Treasury stock, at cost -- 4,000 shares in 2006	(4,200)	-
Total stockholders' equity (deficit)	(5,093,725)	(4,819,629)
	$        676,822	$         165,370

See accompanying notes to financial statements.

3

CAPACITIVE DEIONIZATION TECHNOLOGY SYSTEMS, INC.

(A Development Stage Entity)

STATEMENTS OF OPERATIONS

Three Months Ended March 31, 2006 and 2005

And Cumulative Operations as a Development Stage Entity (January 1, 2000 Through March 31, 2006)

(Unaudited)

			Cumulative
			Through
	2006	2005	March 31, 2006
Revenues	$                     -	$                 -	$             15,000
Operating expenses:
Cost of sales	-	-	10,935
Common stock and options issued for services --
General and administrative	222,170	57,078	2,416,754
Common stock and options issued for services --
Research and development	123,141	17,450	569,055
Other research and development	503,452	159,508	5,141,876
General and administrative (excluding
amounts applicable to stock and options
issued for services each period	251,481	155,073	2,832,217
	1,100,244	389,109	10,970,837
Loss from operations	(1,100,244)	(389,109)	(10,955,837)
Other income (expense):
Other	133,610	-	141,195
Amortization of debt discount	(106,466)	-	(106,466)
Interest expense	(181,286)	(138,749)	(1,175,322)
Total other expense	(154,142)	(138,749)	(1,140,593)
Net loss	$       (1,254,386)	$        (527,858)	$    (12,096,430)
Basic and diluted net loss per common share:	$                (0.05)	$              (0.03)
Weighted average common shares outstanding	24,107,850	19,543,343

See accompanying notes to financial statements.

4

CAPACITIVE DEIONIZATION TECHNOLOGY SYSTEMS, INC.

(A Development Stage Entity)

STATEMENTS OF CASH FLOWS

Three Months Ended March 31, 2006 and 2005

And Cumulative Operations as a Development Stage Entity (January 1, 2000 Through March 31, 2006)

(Unaudited)

			Cumulative
			Through
	2006	2005	March 31, 2006
Cash flows from operating activities:
Net loss	$        (1,254,386)	$        (527,858)	$    (12,096,430)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation	6,358	1,700	43,519
Amortization of debt discount	106,466	-	106,466
Shares issued for services	324,885	66,867	2,401,658
Stock options and warrants issued as compensation	20,426	7,661	586,185
Writedown of note receivable	-	-	140,611
Changes in operating assets and liabilities:
Note receivable	-	-	(40,000)
Accounts payable and accrued liabilities	28,033	125,113	2,828,838
Net cash used in operating activities	(768,218)	(326,517)	(6,029,153)
Cash flows from investing activities:
Purchase of furniture and equipment	(42,435)	(29,824)	(186,390)
Purchase of treasury stock	(4,200)	-	(4,200)
Net cash used in investing activities	(46,635)	(29,824)	(190,590)
Cash flows from financing activities:
Sale of common shares	60,428	230,000	2,554,692
Net advances from shareholder	-	-	(96,388)
Net payments on long-term debt	(44,500)	(60,000)	(273,815)
Payments to former subsidiary	-	-	(238,192)
Additions to convertible debt and notes payable	1,274,300	31,500	4,209,098
Proceeds from notes payable to stockholders	-	400,000	161,500
Net cash provided by financing activities	1,290,228	601,500	6,316,895
Net increase in cash and cash equivalents	475,375	245,159	97,152
Cash at beginning of period	11,178	355,586	389,401
Cash at end of period	$             486,553	$           600,745	$            486,553
Supplemental disclosure:
Total interest paid	$                 5,400	$               3,700	$              49,043

Non-cash transactions:

During 2005, the Company issued 46,000 shares for $10,000 in notes payable.

During 2006, the Company issued 276,000 shares for $55,500 in wages payable and accrued interest.

During 2006, the Company issued 901,000 shares for $180,200 in prepaid loan costs, accounted for as debt discount.

During 2006, the Company issued 4,517,900 warrants to acquire common shares at $.25 per share

   for $343,535 in prepaid loan costs.

See accompanying notes to financial statements.

5

CAPACITIVE DEIONIZATION TECHNOLOGY SYSTEMS, INC.

NOTES TO FINANCIAL STATEMENTS

March 31, 2006

Note 1 - Future Operations

     The Company's financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company's significant operating losses and its working capital deficit and stockholders' deficit raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

     The following is a summary of management's plan to raise capital and generate additional operating funds.

The Company was funded initially through investment by its co-founder. Since 1998 funding has been through private placements.

The Company recognizes the extent of the financial investment necessary to support the planned business activities. There is no guarantee that the Company can complete the above-referenced financing; however, the Company is negotiating the following options:

*         An offering on the London Stock Market (Alternative Investment Market - "AIM")

*         Financing of our manufacturing facility with a Native American Tribe

*         Expansion of current strategic and investment alliances

*         An alliance with industry and government partners to accelerate pilot systems for the
             Powder River CBME Gas Wastewater Remediation Project

Business opportunities will rely on the Company executing its polymerization and pyrolization and assembly outsourcing plans. The Company's plans to produce over 3,000 Aqua Cells in the next twelve months is dependent on financing and expanding outsourcing capacities.

To meet the 2006 and 2007 requirements, the Company must obtain the working capital necessary for its planned Oklahoma manufacturing facility, capital equipment and required personnel. To meet these needs, capital must be received or committed by mid-year.

The Company has expanded its commitment to developing a team of strategic partners by providing demonstration AquaCells for technology and application testing. To date, demonstration AquaCells are implemented in Japan, Australia, Holland and Canada, as well as the U.S. Ongoing CDT application development is active at Texas A&M University, Texas Water Development Board, as well as several multi-national corporate strategic partners' identified applications.

6

There can be no assurances given that the Company will be successful in generating sufficient revenues from its planned activities or in raising sufficient capital to allow it to continue as a going concern which contemplates increased operating expenses, acquisition of assets and the disposition of liabilities in the normal course of business. These factors can affect the ability of the Company to implement its general business plan including the completion of the required manufacturing facilities and continued proprietary CDT product improvements.

Note 2   Summary of Significant Accounting Policies and Practices

     (a)   Description of Business

  Capacitive Deionization Technology Systems, Inc. (Formerly FarWest Group, Inc.) (the "Company" or "CDT Systems, Inc.") was organized under the laws of the state of Nevada in July 1996 to serve as a water technology company.

     In January 1997, the Company entered into a manufacturing and marketing license agreement with Lawrence Livermore National Laboratories ("Lawrence Livermore") whereby the Company obtained the rights to Lawrence Livermore's patented Capacitive Deionization Technology ("CDT"). The Company has the rights to develop and manufacture a carbon aerogel CDT product for commercial use in the desalination, filtration and purification of water. The manufacturing and marketing license is effective for the life of the patents (up to 17 years). To maintain the license the Company must make contracted annual royalty payments to Lawrence Livermore beginning at $25,000 per year, then becoming a percentage of revenue.

     (b) Net Loss per Weighted Average Share

     Net loss per weighted average share is calculated using the weighted average number of shares of common stock outstanding.

     (c) Basis of Presentation

     The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-QSB of Regulations S-B. They do not include all information and footnotes required by generally accepted accounting principles for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the notes to the financial statements for the year ended December 31, 2005 which has been included in the Company's Annual Report on Form 10-KSB filed with the Securities and Exchange Commission. The interim unaudited financial statements should be read in conjunction with those financial statements to be included in the Form 10-KSB. In the opinion of management, all adjustments considered necessary for a fair presentation, consisting solely of normal recurring adjustments, have been made. Operating result s for the three months ended March 31, 2006 are not indicative of the results that may be expected for the year ending December 31, 2006.

7

(d) Stock-Based Compensation

The Company applies the provisions of Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees" and related interpretations, in accounting for its stock-based compensation plans. Under Opinion 25, compensation cost is measured as the excess, if any, of the market price of the Company's stock at the date of the grant above the amount an employee must pay to acquire the stock. No compensation expense is recognized when the exercise price is equal to the market value of the stock on the day of the grant. The Financial Standards Board ("FASB") published SFAS No. 123, "Accounting for Stock-Based Compensation" (SFAS No. 123) on January 1, 1996 which encourages, but does not require, companies to recognize compensation expense for grants of stock, stock options and other equity instruments to employees based on new fair value accounting rules. Companies that choose not to adopt the new rules will continue to apply the existing rules, but will be required to disclose p ro forma net income under the new method.

During the quarter ended March 31, 2005, the Company issued 150,000 options to an employee, exercisable rateably over five years at $.22 per share. The effect on pro forma net loss and net loss per share was nominal. During the quarter ended March 31, 2006, the Company issued 925,000 options to employees, exercisable rateably over 5 years at $.17 per share. The Company expensed $20,426 in connection with the options.

During the quarter ended March 31, 2006, the Company issued 4,517,900 three-year warrants to acquire shares of the Company's common stock at $.25 per share in connection with the issuance of certain short-term debt. The value of these warrants amounted to $343,535. The Company also issued 901,000 shares of common stock, valued at $180,200, in connection with the debt. These amounts, aggregating $523,735, have been recognized as a discount on the short-term debt and are being amortized over the six-month maturity of the debt.

Item 2 Management's discussion and analysis of financial condition and results of operations.

     Results of operations.

To date the Company has recognized nominal revenue. General and administrative expenses were increased to $251,481 in the first quarter of 2006 compared to $155,073 in the first quarter of 2005, principally to expand the Company's infrastructure and financing efforts. Research and development expenditures for the first quarter of 2006 increased to $503,452 compared to $159,508 in the first quarter of 2005 due to the Company's continued development of its AquaCell technology. R & D expenses totaled 57% of operating expenses in the first quarter of 2006 compared to 46% in 2005.

During the first quarter of 2006, the Company wrote off certain old liabilities amounting to $133,610. The credit is included as other income in the accompanying statement of operations.

8

Liquidity and capital resources.

Management recognizes the requirement for additional investment to execute the Company's business plan and complete the necessary manufacturing and research facilities. Financing transactions are currently being negotiated. These include an entity providing funding necessary to finance the manufacturing facility, an offering on the London Stock Exchange, continued interim financing and long-term asset financing. There is no certainty that these fundings will be completed.

See Part II, Item 2 below regarding the Company's financing activities in the first quarter 2006.

     Information regarding and factors affecting forward-looking statements. Forward-looking statements include statements concerning plans, goals, strategies, future events or performances and underlying assumptions and other statements, which are other than statements of historical fact. Certain statements contained herein are forward-looking statements and, accordingly, involve risk and uncertainties, which could cause the actual results or outcomes to differ materially from those expressed in the forward-looking statements. The Company's expectations, beliefs and projections are expressed in good faith and are believed by the Company to have a reasonable basis, including without limitations, management's examination of historical trends, data contained in the Company's records and other data available from third parties, but there can be no assurance that management's expectations, beliefs or projections will result, or be achieved, or accomplished.

Item 3. Controls and Procedures

    (a)Evaluation of disclosure controls and procedures.

The Company's principal executive and financial officers have conducted an evaluation of the effectiveness of the Company's disclosure controls and procedures pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934 as of a date (the "Evaluation Date") at the end of the period. Based upon that evaluation, the Company's principal executive and financial officers have concluded that, as of the Evaluation Date, the Company's disclosure controls and procedures were effective in ensuring that all material information relating to the Company required to be filed in this quarterly report has been made known to them in a timely manner.

    (b)Changes in internal controls.

There have been no significant changes made in the Company's internal controls or in other factors that has materially affected or is reasonably likely to materially affect internal controls over financial reporting.

Part II.    Other Information

Item 2. Unregistered Sales of Equity Securities

Set forth below is information regarding the issuance and sales of our securities without registration during the first quarter of 2006. Except as otherwise noted, all sales below were made in reliance on Section 4(2) of the Securities Act of 1933, as amended and no such sales involved the use of an underwriter and no commissions were paid in connection with the sale of any securities. No advertising or general solicitation was employed in offering the securities. In each instance, the offerings and sales were made to a limited number of persons, who were either (i) accredited investors, (ii) business associates of the Company (iii) employees of the Company, or (iv) executive officers or directors of the Company. In addition, the transfer of such securities were restricted by the Company in accordance with the requirements of the Act. Furthermore, all of the above-referenced persons were provided with access to our filings with the Securities and Exchange Commission.

9

During the first quarter 2006, 15% short-term loans, generally with six-month maturities, provided $1,274,300 to the Company. Certain of these notes are convertible into 770,000 shares of the Company's common stock at $.50 per share. The noteholders also received 4,517,900 three-year warrants to acquire shares of the Company's common stock at $.25 per share. In addition, a private placement to individual accredited investors of 3,102,425 shares of the Company's restricted common stock was completed. The private placement provided the Company $60,428 in cash through the issuance of 301,000 shares; 615,705 shares were issued for $123,141 of engineering services: 800,000 shares were issued for $160,000 of financial consulting services for the Oklahoma manufacturing facility; 208,720 shares were issued for $41,744 of professional services; 901,000 shares were issued for $180,200 of prepaid loan costs and 276,000 shares were issued to settle $55,500 of accrued wages and accrued interest.

Item 6. Exhibits

31.1	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

SIGNATURE

     Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this amended report to be signed on its behalf by the undersigned thereunto duly authorized.

Capacitive Deionization Technology Systems, Inc.

/s/ Dallas Talley                       

Dallas Talley

Chairman of the Board,

Chief Executive Officer

Dated: May 12, 2006

Capacitive Deionization Technology Systems, Inc.

/s/ Phil Marshall                 

Phil Marshall

Chief Financial Officer

Dated: May 12, 2006

10

EX-31

EXHIBIT 31.1

CERTIFICATION PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Dallas Talley, certify that:

1.	I have reviewed this quarterly report on Form 10-KSB of Capacitive Deionization Technology Systems, Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of Capacitive Deionization Technology Systems, Inc. as of, and for, the periods presented in this report;
4.	Capacitive Deionization Technology Systems, Inc.'s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for Capacitive Deionization Technology Systems, Inc. and have:
	(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to Capacitive Deionization Technology Systems, Inc., including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	(c) Evaluated the effectiveness of Capacitive Deionization Technology Systems, Inc.'s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	(d) Disclosed in this report any change in Capacitive Deionization Technology Systems, Inc.'s internal control over financial reporting that occurred during Capacitive Deionization Technology Systems, Inc.'s most recent fiscal year that has materially affected, or is reasonably likely to materially affect, Capacitive Deionization Technology Systems, Inc.'s internal control over financial reporting; and
5.	Capacitive Deionization Technology Systems, Inc.'s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Capacitive Deionization Technology Systems, Inc.'s independent registered public accounting firm and the audit committee of Capacitive Deionization Technology Systems, Inc.'s board of directors (or persons performing the equivalent functions):
	(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect Capacitive Deionization Technology Systems, Inc.'s ability to record, process, summarize and report financial information; and
	(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in Capacitive Deionization Technology Systems, Inc.'s internal control over financial reporting.

Date: May 12, 2006	/s/ Dallas Talley
	Chief Executive Officer

EX-31

EXHIBIT 31.2

CERTIFICATION PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Phil Marshall, certify that:

1.	I have reviewed this quarterly report on Form 10-KSB of Capacitive Deionization Technology Systems, Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of Capacitive Deionization Technology Systems, Inc. as of, and for, the periods presented in this report;
4.	Capacitive Deionization Technology Systems, Inc.'s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for Capacitive Deionization Technology Systems, Inc. and have:
	(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to Capacitive Deionization Technology Systems, Inc., including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	(c) Evaluated the effectiveness of Capacitive Deionization Technology Systems, Inc.'s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	(d) Disclosed in this report any change in Capacitive Deionization Technology Systems, Inc.'s internal control over financial reporting that occurred during Capacitive Deionization Technology Systems, Inc.'s most recent fiscal year that has materially affected, or is reasonably likely to materially affect, Capacitive Deionization Technology Systems, Inc.'s internal control over financial reporting; and
5.	Capacitive Deionization Technology Systems, Inc.'s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Capacitive Deionization Technology Systems, Inc.'s independent registered public accounting firm and the audit committee of Capacitive Deionization Technology Systems, Inc.'s board of directors (or persons performing the equivalent functions):
	(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect Capacitive Deionization Technology Systems, Inc.'s ability to record, process, summarize and report financial information; and
	(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in Capacitive Deionization Technology Systems, Inc.'s internal control over financial reporting.

Date: May 12, 2006	/s/ Phil Marshall
	Chief Financial Officer

EX-32

EXHIBIT 32.1

CERTIFICATION PURSUANT TO RULE 13a-14(b) OR

RULE 15d-14(b) and 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Capacitive Deionization Technology Systems, Inc. (the "Company") on Form 10-QSB for the quarter ended March 31, 2006 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Dallas Talley, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

       (1)       The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

       (2)       The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 12, 2006	/s/ Dallas Talley
	Chief Executive Officer

EX-32

Exhibit 32.2

CERTIFICATION PURSUANT TO RULE 13a-14(b) OR

RULE 15d-14(b) and 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Capacitive Deionization Technology Systems, Inc. (the "Company") on Form 10-QSB for the quarter ended March 31, 2006 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Phil Marshall, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

       (1)       The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

       (2)       The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 12, 2006	/s/ Phil Marshall
	Chief Financial Officer